Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025
Elutia (Nasdaq: ELUT), a company specializing in drug-eluting biomatrix technologies, has scheduled the release of its Q1 2025 financial results for Thursday, May 8, 2025, after market close. The management team will host a conference call and webcast at 5:00 p.m. Eastern Time on the same day. U.S. investors can join via 877-407-8029, while international investors can dial 201-689-8029 using Conference ID 13753035. A live and archived webcast will be available on the company's investor relations website.
Elutia (Nasdaq: ELUT), azienda specializzata in tecnologie biomatrici a rilascio di farmaci, ha programmato la pubblicazione dei suoi risultati finanziari del primo trimestre 2025 per giovedì 8 maggio 2025, dopo la chiusura del mercato. Il team di gestione terrà una conference call e una webcast alle 17:00 ora della costa orientale dello stesso giorno. Gli investitori statunitensi possono partecipare chiamando il numero 877-407-8029, mentre gli investitori internazionali possono utilizzare il numero 201-689-8029 con il codice di conferenza 13753035. Una webcast in diretta e registrata sarà disponibile sul sito web delle relazioni con gli investitori della società.
Elutia (Nasdaq: ELUT), empresa especializada en tecnologías de biomatrices con liberación de fármacos, ha programado la publicación de sus resultados financieros del primer trimestre de 2025 para el jueves 8 de mayo de 2025, después del cierre del mercado. El equipo directivo realizará una llamada conferencia y una transmisión en vivo a las 5:00 p.m., hora del Este del mismo día. Los inversionistas en EE. UU. pueden unirse marcando el 877-407-8029, mientras que los inversionistas internacionales pueden llamar al 201-689-8029 usando el ID de conferencia 13753035. Habrá una transmisión en vivo y archivada disponible en el sitio web de relaciones con inversionistas de la compañía.
Elutia (나스닥: ELUT)는 약물 방출 바이오매트릭스 기술을 전문으로 하는 회사로, 2025년 5월 8일 목요일 장 마감 후 2025년 1분기 재무 결과를 발표할 예정입니다. 경영진은 같은 날 동부 표준시 오후 5시에 컨퍼런스 콜과 웹캐스트를 진행합니다. 미국 투자자는 877-407-8029로, 해외 투자자는 201-689-8029에 회의 ID 13753035를 사용하여 참여할 수 있습니다. 생중계 및 녹화된 웹캐스트는 회사의 투자자 관계 웹사이트에서 제공됩니다.
Elutia (Nasdaq : ELUT), une entreprise spécialisée dans les technologies de biomatrices à libération de médicaments, a prévu de publier ses résultats financiers du premier trimestre 2025 le jeudi 8 mai 2025, après la clôture du marché. L'équipe de direction organisera une conférence téléphonique et une webdiffusion à 17h00, heure de l'Est, le même jour. Les investisseurs américains peuvent participer en appelant le 877-407-8029, tandis que les investisseurs internationaux peuvent composer le 201-689-8029 en utilisant l'ID de conférence 13753035. Une webdiffusion en direct et en différé sera disponible sur le site des relations investisseurs de la société.
Elutia (Nasdaq: ELUT), ein Unternehmen, das sich auf medikamentenfreisetzende Biomatrix-Technologien spezialisiert hat, hat die Veröffentlichung seiner Finanzergebnisse für das erste Quartal 2025 für Donnerstag, den 8. Mai 2025, nach Börsenschluss angekündigt. Das Management-Team wird am selben Tag um 17:00 Uhr Eastern Time eine Telefonkonferenz und Webcast veranstalten. US-Investoren können unter 877-407-8029 teilnehmen, internationale Investoren wählen 201-689-8029 mit der Konferenz-ID 13753035. Ein Live- und ein archivierter Webcast werden auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its first quarter 2025 financial results after market close on Thursday, May 8, 2025. Members of the Company’s management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day.
The conference call can be accessed using the following information:
Webcast: Click here
U.S. Investors: 877-407-8029
International Investors: 201-689-8029
Conference ID: 13753035
Please log in approximately 10 minutes prior to the scheduled start time. A live and archived webcast of the event will be available on the “Investors” section of the Elutia website at http://investors.elutia.com/.
About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.
Investors:
Matt Steinberg
FINN Partners
matt.steinberg@finnpartners.com
This press release was published by a CLEAR® Verified individual.
FAQ
When will Elutia (ELUT) release its Q1 2025 earnings?
What time is Elutia's Q1 2025 earnings call?
How can I join Elutia's Q1 2025 earnings call?
Where can I find the webcast of Elutia's Q1 2025 earnings call?
